Inhibition of catalytic site common to multiple 3 alpha-oxidoreductases for treatment of prostate cancer
OwnerJames L. Mohler, Michael Fiandalo +2inventors
InventorsJames L. Mohler, Michael Fiandalo, David Watt, Elizabeth Wilson
Life of this patent
Estimating the term…
Abstract
A method of inhibiting activity or expression of one or more 3α-oxidoreductase enzymes that share a common catalytic site and convert androstanediol to DHT. The method comprises introducing one or more agents into cells that comprise the one or more 3α-oxidoreductase enzymes, wherein said one or more agents: i) inhibit function of one or more of said enzymes; ii) inhibit translation of mRNA encoding said enzymes; iii) disrupt or delete genes encoding said enzymes; or a combination thereof.
Claims15
A method of inhibiting activity or expression of one or more 3α-oxidoreductase enzymes that share a common catalytic site and convert androstanediol to DHT, the method comprising introducing one or more agents into cells that comprise the one or more 3α-oxidoreductase enzymes, wherein said one or more agents:
- i) inhibit function of one or more of said enzymes;
- ii) inhibit translation of mRNA encoding said enzymes;
- iii) disrupt or delete genes encoding said enzymes;
- or a combination thereof.
Dependencies are inferred from the claim text.